Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.
Research context
Aequus Pharmaceuticals Inc appears in PyInvesting’s TSX Venture Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Aequus Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 21.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.2.
Aequus Pharmaceuticals Inc's total revenue rose by 66.9% to $619K since the same quarter in the previous year.
Its net income has increased by 61.9% to $-252K since the same quarter in the previous year.
Finally, its free cash flow grew by 81.1% to $-105K since the same quarter in the previous year.
Based on the above factors, Aequus Pharmaceuticals Inc gets an overall score of 4/5.